Lp(a), pronounced L-P-little-a, is an inherited cholesterol particle that multiplies heart-attack risk when it runs high and it is absent from the standard lipid panel that nearly every annual physical in America orders. So why has your doctor never tested it? The absence has a reason and the reason is not that the particle does not matter. The European Atherosclerosis Society calls it the most common genetically determined cardiovascular risk factor and the standard panel never measures it. One blood draw settles the question for life. Your Lp(a) level is set by your genetics and stays stable across adulthood.

Key takeaways
  • Lp(a) is a genetic lipoprotein absent from the standard lipid panel ordered at most annual physicals.
  • Measuring it once, in adulthood, settles the question for life because the level is genetically set and stable.
  • Elevated Lp(a) multiplies the risk carried by ApoB and does not respond to diet.
  • The Biomarker Audit reads Apolipoprotein B (ApoB) and Lipoprotein (A) at every quarterly draw, included in the flat $299 membership.
  • Any prescription follows your labs and is billed by the pharmacy at its own cost with zero markup.

What Lp(a) actually is

Lp(a) is an LDL-like particle that carries a unique protein called apolipoprotein(a), covalently attached to ApoB. It travels in the blood like LDL. Its extra protein component makes it both more atherogenic and harder to clear than ordinary LDL particles. Levels are set almost entirely by the LPA gene and remain stable from early adulthood onward, so one accurate measurement in adulthood characterizes the individual for life.

Measurement matters because Lp(a) is invisible to the standard lipid panel and because it does not respond meaningfully to lifestyle intervention. Diet and exercise lower LDL-C and ApoB, but they do not move Lp(a). That is precisely why the number is worth knowing. Unlike the markers you can improve, Lp(a) changes who your risk is and what your ApoB target should be.

Why the standard annual panel skips it

The standard lipid panel orders total cholesterol, LDL-C, HDL-C and triglycerides. It does not order ApoB or Lp(a). Cost, historical scope and guideline lag all play a role. None of those reasons changes the biology. The European Atherosclerosis Society consensus statement recommends Lp(a) measurement once in every adult's lifetime for cardiovascular risk assessment. National cardiovascular societies including the National Lipid Association and the American Heart Association have endorsed screening in selected higher-risk adults.

The consequence is practical. An annual physical that reports normal cholesterol can sit beside an Lp(a) measured in the 95th percentile, because the standard panel counts cholesterol mass and never reads the particle that carries the genetic risk. Family history of early heart attack is the clinical flag that most often should trigger this test and most often does not.

There is a second reason the number stays unmeasured inside per-visit billing. In the conventional system each additional test is a line item on a receipt and the visit that would explain it is another one, so the panel grows only when symptoms have argued long enough to win the argument. Nobody argues for a test nobody has heard of. A particle you cannot feel, that produces no symptom until an event, loses that argument every time in a system paid per line item.

What to do with a high number

A high Lp(a) is not a treatment target in the way LDL is. There is no pill that reliably lowers it today and no lifestyle program that lowers it either, so the clinical value of the measurement is entirely in what it changes about everything else.

An elevated Lp(a) tightens the ApoB target, because the two risks multiply rather than add. A person with Lp(a) in the 95th percentile and an ApoB of 110 mg/dL carries materially more risk than either number alone suggests. The honest response is to drive the modifiable marker, ApoB, toward the low end of the range rather than to accept a midpoint. Statins, ezetimibe and where indicated PCSK9 inhibitors all lower ApoB. The choice among them is a clinical question that follows the panel. Lp(a)-directed therapies exist in trials but they are not approved for general use and we do not prescribe them outside trials.

Clinical note

Lp(a) changes who your risk is. ApoB is the marker you can fix and the quarterly audit tracks both.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

How the Biomarker Audit handles Lp(a)

The quarterly Cardiometabolic Optimization Panel includes Apolipoprotein B (ApoB) and Lipoprotein (A) at every draw, alongside Fasting Insulin, Hs-CRP, Hemoglobin A1c (HbA1c), a Lipid Panel, Standard, TSH With Reflex To Free T4 and CBC (Includes Differential And Platelets). Reading the two cardiovascular markers together is the point. ApoB is the modifiable number and Lp(a) is the inherited multiplier. The clinical protocol treats them as a pair.

The audit repeats every 90 days inside the flat $299 monthly membership. The trend, rather than any single draw, is what the clinician treats. Lp(a) itself does not need to be re-measured at every draw once it is characterized, because it is genetically set. What changes at each audit is ApoB and the treatment decision it drives.

Family history is the flag that should have caught it

The most common way elevated Lp(a) is discovered today is after the fact, in the cardiac catheterization lab of a person whose cholesterol was always called fine. The screening question that catches it beforehand is simple and almost never asked in an eight-minute visit. Did a parent, sibling or grandparent have a heart attack or a stroke before 60? A yes to that question belongs next to a lipid panel that includes Lp(a) and ApoB. A no does not retire the question either, because roughly one in five people with elevated Lp(a) has no family history to point at.

If that yes describes your family, you have probably spent years collecting normal cholesterol reports that never answered it. The test that answers it is one draw. It is already on our panel and it is included in the membership fee rather than billed as a line item.

What the first year looks like

The eligibility check is free and takes a few minutes. A clinician reviews your history and either accepts you into care or does not. The $598 hold on your card converts to a charge only on acceptance. The first Biomarker Audit is ordered within days, you fast overnight and the draw takes minutes at a patient service center near you. When the results land, your clinician walks the whole panel with you, including the two cardiovascular markers together and what your ApoB target should be given where your Lp(a) sits.

The quarterly cadence then does the work a single snapshot cannot. ApoB moves with treatment and the audit shows the movement, four times a year, with the protocol adjusted at each reading. Over twelve months the membership totals $3,588 and it includes four full audits and the clinical relationship that reads them. The comparison that matters is against the decade of standard panels that never measured the particle at all.

Who this is for and who it is not for

This is for the reader with early heart disease in the family and normal cholesterol reports that never explained it, the Concierge Longevity Optimizer who wants the cardiovascular picture read at depth rather than screened and the high-deductible patient who pays cash for labs anyway and would rather have one defined fee than per-test billing with nobody reading the trend.

It is not for someone who wants a single lipid slip with no clinical relationship attached. Labs-only services exist for exactly that purchase. It is not for anyone outside the United States, because our clinicians are licensed in the fifty states. And it is not insurance. The membership pairs with a plan for catastrophic coverage and replaces the primary-care relationship, not the policy.

What it costs, stated plainly

The Cardiometabolic Optimization Membership is one flat $299 per month covering the clinical relationship and four quarterly Biomarker Audits a year. It starts with a two month commitment paid as a single $598 hold covering the first two months together, charged only once a clinician accepts you into care. If no clinician can accept you, the hold is released and you are never charged. Once accepted, the first two months are non-refundable. From month three the membership is month to month and you can cancel anytime.

Medication is a separate charge and it never flows through us. Any prescription is written to the pharmacy you choose and billed by that pharmacy at its own price. GoodLife Health sets nothing, sees nothing and takes nothing on that transaction. There is no molecule upcharge and no dose upcharge, ever. One flat fee for the doctor. Zero markup on the medicine. The eligibility check is free and takes a few minutes.

Frequently Asked Questions

What is Lp(a)?

Lp(a) is an inherited LDL-like cholesterol particle that multiplies cardiovascular risk when elevated. It is set by genetics, stable across adulthood and invisible to the standard lipid panel, which is why it is usually never tested.

Why has my doctor never tested Lp(a)?

The standard lipid panel does not include it, guideline adoption has lagged the science and most annual physicals are ordered around the standard panel. Family history of early heart attack is the clinical flag that should trigger the test and most often does not.

How often should Lp(a) be measured?

Once in adulthood is enough to characterize it for life, because the level is genetically set and stable. What changes over time is ApoB, which is the modifiable marker the Lp(a) result tightens.

Can Lp(a) be lowered?

Not reliably today. Lifestyle intervention does not move it and no approved therapy lowers it meaningfully. The clinical response is to drive the modifiable marker, ApoB, toward the low end of the range.

What is a high Lp(a)?

Laboratories report different units and cut points, so the interpretation belongs to the clinician reading your full panel. What matters is that an elevated value is an inherited risk multiplier, not a lifestyle failure.

Is Lp(a) included in the Biomarker Audit?

Yes. Lipoprotein (A) is part of the quarterly Cardiometabolic Optimization Panel, alongside ApoB, fasting insulin, HbA1c, hs-CRP, the lipid panel, thyroid and CBC. It is included in the flat $299 membership, four audits a year.

Does the fee change with my prescription?

No. The fee is one flat $299 per month covering the doctor and the quarterly panel. Medication is billed by your pharmacy separately at pharmacy cost with zero markup, so the fee never rises with the dose.

One last thing

If a parent or sibling had a heart attack before 60 and your cholesterol has been called normal for a decade, the most likely reason is that nobody ever ordered the one test that explains it. Lp(a) is that test. It is on our panel at every audit and it is included in the membership. The eligibility check is where it starts.

Related Guides

References

  1. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement, European Heart Journal, 2022. pubmed.ncbi.nlm.nih.gov/36036785
  2. American Heart Association, what your cholesterol levels mean. heart.org